Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

65.17 -0.03 (-0.04%)
Streaming Delayed Price Updated: 10:29 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Recap: Gilead Sciences Q3 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021. 
Via Investor's Business Daily
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
GILD: Is This Biotech’s 4.2% Yield Healthy?
Gilead’s free cash flow hit a recent peak of $19.5 billion in 2015 before falling each of the next two years, settling around $7.5 billion in 2018. 
Via Talk Markets
Gilead Sciences Earnings Preview
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
It's much too early to count these companies out. 
Via The Motley Fool
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
2 High-Yielding Stocks You Can Buy and Hold for Years
They pay more than double what the average S&P 500 stock yields. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
Signs point to yes, but it's still early in the game. 
Via The Motley Fool
Exposures COVID-19
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster... 
Via Benzinga
Exposures COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
A new study shows it is highly effective in preventing deaths if taken early. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19.... 
Via Benzinga
Exposures COVID-19
Tesla and Merck Give Investors Some Hope
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
3 Top Dividend Stocks Yielding More Than 4%
Make the most of your money with these generous income stocks. 
Via The Motley Fool
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory... 
Via Benzinga
Exposures COVID-19
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for... 
Via Benzinga
Exposures Product Safety
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval... 
Via Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New... 
Via Benzinga
Exposures COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.